Metagenomi Presents Highly Specific and Efficient Genome Editing Tools at Nature Conference “RNA at the Bench and Bedside IV”
11. Dezember 2024 18:30 ET
|
Metagenomi, Inc.
MGX-001, utilizing a highly specific and efficient MG29-1 nuclease, exhibits no identifiable off-target editing MG29-1 nuclease targeting the albumin safe harbor locus showed no evidence of...
Metagenomi Presents Updated Preclinical Data in Hemophilia A at American Society of Hematology (ASH) 66th Annual Meeting
09. Dezember 2024 21:16 ET
|
Metagenomi, Inc.
Therapeutically relevant levels of Factor VIII (FVIII) activity sustained in ongoing nonhuman primate (NHP) study through more than sixteen months of follow up MGX-001 bioengineered FVIII construct...
Metagenomi Reports Business Updates and Third Quarter 2024 Financial Results
13. November 2024 16:05 ET
|
Metagenomi, Inc.
Initiating IND-enabling activities for MGX-001 development candidate (DC) in hemophilia A; Achieved durable Factor VIII activity levels over twelve months in nonhuman primate (NHP) study On track for...
Metagenomi To Present New Preclinical Hemophilia A Data at American Society of Hematology (ASH) 66th Annual Meeting
05. November 2024 16:05 ET
|
Metagenomi, Inc.
EMERYVILLE, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its...
Metagenomi Presents Novel, Highly Specific and Efficient Adenine Base Editors for Broad Genome Editing at ESGCT
24. Oktober 2024 08:04 ET
|
Metagenomi, Inc.
Metagenomi Adenine Base Editors (ABEs) demonstrated over 95% genome targetability Simultaneous ABE triplex editing resulted in over 95% protein knockdown in primary T-cells ABE demonstrated highly...
Metagenomi Presents Compact SMART Editing Platform at AIChE 7th International Conference on CRISPR Technologies
14. Oktober 2024 20:58 ET
|
Metagenomi, Inc.
Poster presentation highlights SMART adenine base editors (ABEs)small enough to be packaged into a single adeno-associated virus (AAV) Data demonstrate compact SMART system optimizations allowing...
Metagenomi to Present at Chardan's 8th Annual Genetic Medicines Conference
19. September 2024 19:15 ET
|
Metagenomi, Inc.
EMERYVILLE, Calif., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its...
Metagenomi Announces Preclinical Data for Lead Hemophilia A Program Demonstrating Durable Factor VIII (FVIII) Activity Levels through Twelve Months
03. September 2024 16:05 ET
|
Metagenomi, Inc.
Twelve-month durability data from Metagenomi’s ongoing nonhuman primate (NHP) study in hemophilia A remains generally consistent with data previously released at 4.5 months NHPs remain healthy and...
Metagenomi Presents AI-Enabled Advancements of SMART Editing Platform at the Cold Spring Harbor Laboratory CRISPR Frontiers Conference
29. August 2024 19:32 ET
|
Metagenomi, Inc.
AI-generated, compact SMART nucleases demonstrated robust genome editing activity in vitro in mammalian cells at multiple therapeutically relevant loci Compact SMART genome editing tools that...
Metagenomi to Participate in Upcoming Investor Conferences
28. August 2024 18:10 ET
|
Metagenomi, Inc.
EMERYVILLE, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its...